{
  "ticker": "JNJ",
  "target_date": "2025-05-05",
  "actual_date": "2025-05-05",
  "collected_at": "2025-12-08T11:43:20.180334",
  "price": {
    "open": 153.23,
    "high": 153.35,
    "low": 151.34,
    "close": 151.60012817382812,
    "volume": 5464100,
    "change_1d_pct": -0.72,
    "change_7d_pct": 0.05,
    "change_30d_pct": -5.27
  },
  "technicals": {
    "rsi_14": 52.06,
    "sma_20": 150.82,
    "sma_50": 156.01,
    "macd": -0.686,
    "macd_signal": -0.987,
    "macd_histogram": 0.301,
    "bb_upper": 155.81,
    "bb_lower": 145.83,
    "price_vs_sma20_pct": 0.52,
    "price_vs_sma50_pct": -2.83,
    "volume_ratio": 0.57
  },
  "fundamentals": {
    "market_cap": 489351938048,
    "pe_ratio": 19.605213,
    "forward_pe": 19.16132,
    "price_to_book": 6.1647496,
    "price_to_sales": 5.3104424,
    "profit_margin": 27.26,
    "operating_margin": 30.2,
    "roe": 33.62,
    "roa": 8.26,
    "revenue_growth": 6.8,
    "earnings_growth": 91.0,
    "debt_to_equity": 57.766,
    "current_ratio": 1.074,
    "quick_ratio": 0.711,
    "dividend_yield": 258.0,
    "fifty_two_week_high": 207.81,
    "fifty_two_week_low": 140.68,
    "fifty_day_avg": 193.4922,
    "two_hundred_day_avg": 170.2741,
    "analyst_target": 203.41833,
    "analyst_recommendation": "buy",
    "num_analysts": 24,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -2.26,
    "pct_from_52w_low": 44.38
  },
  "macro": {
    "spy": {
      "price": 560.3,
      "change_1d_pct": -0.57,
      "change_7d_pct": 2.34
    },
    "vix": {
      "level": 23.64,
      "signal": "ELEVATED"
    },
    "treasury_10y": {
      "yield_pct": 4.34
    },
    "dollar_index": {
      "level": 99.83
    },
    "gold": {
      "price": 3311.3
    },
    "regime": "SIDEWAYS"
  },
  "news": [
    {
      "headline": "MedTechs Adjust 2025 Outlook Amid Tariffs: What Investors Need to Know",
      "source": "Yahoo",
      "datetime": 1746471600,
      "summary": "Most of the MedTech players have adjusted their 2025 forecasts in response to rising tariff pressure.",
      "url": "https://finnhub.io/api/news?id=8eca391ed878559f19580d58c5c15add9e62bbf25f3ad831fb24fb413981660c"
    },
    {
      "headline": "Bristol Myers to invest $40 billion in the US over 5 years, CEO says",
      "source": "Finnhub",
      "datetime": 1746466193,
      "summary": "Bristol Myers Squibb willspend $40 billion in the US over the next five years, CEOChristopher Boerner wrote in an opinion piece published by StatNews on Monday. Boerner said the money...",
      "url": "https://finnhub.io/api/news?id=981336b67f57a91f9e6627f928f0fe8decb33ef6321ca5e2ee511d7be2a770b4"
    },
    {
      "headline": "Was Jim Cramer Right About Johnson & Johnson (JNJ)?",
      "source": "Yahoo",
      "datetime": 1746451762,
      "summary": "We recently published a list of Did Jim Cramer Hit or Miss On These 13 Stock Predictions? In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other stocks that Jim Cramer discussed during the episode of Mad Money on May 1st, 2024. During the Mad Money ep",
      "url": "https://finnhub.io/api/news?id=25dd079a268ca6ccbb4f93b2dca6fcbc1576a0394ec303c604f07bb291031338"
    },
    {
      "headline": "TREMFYA\u00ae (guselkumab) positioned to become the first and only IL-23 inhibitor to offer subcutaneous induction in ulcerative colitis as demonstrated in new data through 24 weeks",
      "source": "Yahoo",
      "datetime": 1746446700,
      "summary": "Johnson & Johnson (NYSE: JNJ) today announced new data from the Phase 3 ASTRO study evaluating TREMFYA\u00ae (guselkumab) subcutaneous (SC) induction therapy in adults with moderately to severely active ulcerative colitis (UC). The ASTRO Week 24 data build on the Week 12 SC induction data that showed sta",
      "url": "https://finnhub.io/api/news?id=096393cdd048cb6de09945dbe21f788135bc2b707a7f1b9dd0f3032f474e0589"
    },
    {
      "headline": "TREMFYA\u00ae (guselkumab) delivers sustained clinical and endoscopic remission in ulcerative colitis through two years",
      "source": "Yahoo",
      "datetime": 1746446700,
      "summary": "Johnson & Johnson (NYSE: JNJ) today announced new data from the TREMFYA\u00ae (guselkumab) Phase 3 QUASAR long-term extension (LTE) study in adults with moderately-to-severely active ulcerative colitis (UC). These data are among 24 abstracts highlighting the Company's research being presented at Digestiv",
      "url": "https://finnhub.io/api/news?id=24ee94a56750103d6524f3a6755b17db073a22807417ca40ca27423670ee4e5c"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "4",
      "date": "2025-05-05",
      "description": "xslF345X05/wk-form4_1746479407.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000143/xslF345X05/wk-form4_1746479407.xml"
    },
    {
      "form": "8-K",
      "date": "2025-04-30",
      "description": "jnj-20250424.htm",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000141/jnj-20250424.htm"
    },
    {
      "form": "4",
      "date": "2025-04-28",
      "description": "xslF345X05/wk-form4_1745877468.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000138/xslF345X05/wk-form4_1745877468.xml"
    },
    {
      "form": "4",
      "date": "2025-04-28",
      "description": "xslF345X05/wk-form4_1745877247.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000135/xslF345X05/wk-form4_1745877247.xml"
    },
    {
      "form": "4",
      "date": "2025-04-28",
      "description": "xslF345X05/wk-form4_1745877141.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000133/xslF345X05/wk-form4_1745877141.xml"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}